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Background: There is an ever-increasing volume of data on host genes that are modulated during HIV infection,
influence disease susceptibility or carry genetic variants that impact HIV infection. We created GuavaH (Genomic
Utility for Association and Viral Analyses in HIV, http://www.GuavaH.org), a public resource that supports multipurpose
analysis of genome-wide genetic variation and gene expression profile across multiple phenotypes relevant to HIV
biology.
Findings: We included original data from 8 genome and transcriptome studies addressing viral and host responses
in and ex vivo. These studies cover phenotypes such as HIV acquisition, plasma viral load, disease progression, viral
replication cycle, latency and viral-host genome interaction. This represents genome-wide association data from more
than 4,000 individuals, exome sequencing data from 392 individuals, in vivo transcriptome microarray data from 127
patients/conditions, and 60 sets of RNA-seq data. Additionally, GuavaH allows visualization of protein variation
in ~8,000 individuals from the general population. The publicly available GuavaH framework supports queries
on (i) unique single nucleotide polymorphism across different HIV related phenotypes, (ii) gene structure and
variation, (iii) in vivo gene expression in the setting of human infection (CD4+ T cells), and (iv) in vitro gene
expression data in models of permissive infection, latency and reactivation.
Conclusions: The complexity of the analysis of host genetic influences on HIV biology and pathogenesis calls for
comprehensive motors of research on curated data. The tool developed here allows queries and supports
validation of the rapidly growing body of host genomic information pertinent to HIV research.
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The field of HIV research has adopted genome-wide tech-
nologies in order to meet the goal of understanding the
complex interplay between host and pathogen. A growing
number of approaches allow the interrogation of DNA
variation (genome-wide genotyping, exome and whole
genome sequencing), RNA variation (transcriptome ana-
lyses by gene expression arrays or deep sequencing), as
well as large-scale functional screens (gene silencing using
siRNA or shRNA, gain of function using gene overexpres-
sion). This is complemented with proteome and protein
interaction analyses. The objective of these studies is to* Correspondence: Jacques.fellay@epfl.ch; Amalio.telenti@chuv.ch
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stated.characterize the behavior of any gene/protein in the con-
text of HIV infection in vitro or in vivo.
These studies are generally evaluated using strict statis-
tics, which are necessary considering the large number
of hypotheses that are simultaneously tested in most
genome-wide scans. In addition, many studies require ex-
ternal validation, such as association results in a separate
set of infected individuals, or expression results across
various biological conditions. Accessing those resources is
complex because raw data, or complete sets of analysis
statistics are rarely available – or require re-contacting the
original sources. Currently, there is a lack of integrated
analysis tools by which researchers can easily access well
curated data; to reinforce their own observations, for ex-
ternal replication or for generation of novel hypotheses.
Our groups have been involved in the generation and
analysis of multiple such large-scale datasets. Thus, we
aimed at building a simple platform that would facilitateLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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http://www.retrovirology.com/content/11/1/6the comparison of genomic and transcriptomic results
across studies, while preserving the scientific interests of
researchers and the privacy of study participants. This
paper describes the structure of GuavaH (Genomic Utility
for Association and Viral Analyses in HIV, http://www.
GuavaH.org) and the central issues of interpretation and
integration of genome-wide association (GWAS), exome
and transcriptome data generated in the context of HIV
research (Figure 1).
GuavaH currently provides results from GWAS of HIV
disease phenotypes including more than 4,000 individuals.
GWAS use large-scale genotyping technology (usually
arrays interrogating 500,000 to 1 million single nucleo-
tide polymorphisms, SNPs) complemented with statis-
tical approaches that allow imputation of millions of
additional variants that are not directly measured by the
assay. The main challenge of GWAS is the stringent
statistical threshold for claiming association (usually
p < 5 × 10-8). The power to identify SNPs associated
with a given phenotype depends on the frequency and
the effect size of the genetic variant, and on sample size.
Thus, large numbers of study participants and meta-
analyses across studies are required. GuavaH includesChromosome
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Figure 1 A summary of available data.association results on HIV control (set point plasma
viral load [1,2] and elite control [3]) and on susceptibil-
ity to infection in a cohort of highly exposed seronega-
tive individuals [4]. In addition to these traditional
GWAS of clinically related outcomes GuavaH includes
data from a recent genome-to-genome analysis of host
genetic variants impacting the nucleic acid sequence of
the infecting virus [5]. The genome-to-genome approach
identifies loci of host-pathogen conflict independently of
clinical data. Thus, GuavaH allows the interrogation of
any SNP across multiple studies and phenotypes, and fa-
cilitates the validation of associations identified in other
studies.
Large amounts of biological and genomic data are gen-
erated by additional emerging technologies. One approach
that is transforming genome analysis is the study of hu-
man exome variation by high-throughput sequencing. In
contrast to genotyping arrays, which only capture rela-
tively common variation, exome sequencing captures all
variants present in the coding regions of the genome:
common, rare, and private. Each individual harbors about
20,000 unique coding variants, including a number of po-
tentially severe functional variants coding for stop codonsHLA-A HLA-C HLA-B
Associated SNPs:
Class I HLA genes:
10
(P
)
20
40
60
GAG PR RT IN VIF TAT GP120 GP41 NEF
1 2 3 4 5 6
log10(VL)
7.1
7.2
7.3
7.4
7.5
7.6
TRIM5  in CD4+ T cells
Ex
pr
es
sio
n
TRIM5  during HIV replication
Fo
ld
 c
ha
ng
e 
(lo
g 2)
Time (hours)
0
2
-2
-4
4
2 6 10 14 18 22
In vivo: In vitro:
G2G:
  Host influence on
  viral variation
  
Gene expression:
  In vivo infection
  In vitro models
Bartha et al. Retrovirology 2014, 11:6 Page 3 of 5
http://www.retrovirology.com/content/11/1/6and for frameshift insertions or deletions [6]. Analyses
are still complex, as there are statistical and functional
limitations to the interpretation of rare variants. GuavaH
provides gene-level/regional p-values and a graphical rep-
resentation of nonsynonymous variants, premature stop
codons and frameshift variants. We include protein-level
sequence variation on a large sample taken from the gen-
eral population (Analysis of more than 8000 exomes from
the Exome Sequencing Project (http://evs.gs.washington.
edu/EVS/)), and on 392 HIV infected individuals. Access
to exome data in the HIV + sample is restricted due to
data protection requirements, but gene-level queries are
possible upon request (contact@guavah.org). This detailed
level of protein sequence variation information allows for
visualization and first-pass estimation of the mutationalCCR5 protein va
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Figure 2 Exome view of CCR5 in GuavaH. A protein is depicted in linear
nonsynonymous changes, red vertical lines representing premature stop codo
(MAF) is plotted above for rare variants (MAF < 0.01) in green, and in purple fo
sequences from more than 8000 individuals from the general population: the
been generally recognized. Panel B – Other than CCR5α32 (shown at amino a
among 392 exomes from HIV-infected individuals.burden of a given gene (i.e. level of conservation or vari-
ation) and provides easy access to the genomic location
and impact of protein variants in human genes that
may be of importance in the HIV life cycle. For example,
Figures 1 and 2 present the exome structure of TRIM5α
and CCR5, respectively. For both genes, the report identi-
fies a number of rare premature stop codons.
The GuavaH resource also includes functional transcrip-
tome analyses from in vivo and in vitro studies. The in vivo
data were obtained by microarray studies of CD4+ T cells
from 127 individuals chronically infected with HIV, and
representing the full spectrum of viral load [7]. These data
can be contrasted with temporal in vitro analysis of the
HIV replication cycle in a T cell line (Sup T1), representing
12 data points from HIV infected cells and 12 data pointsriants in ESP (n=6,247)
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Table 1 Online resources on host genes in HIV biology and disease
Web site URL Content
Associated sites to GuavaH
PEACHi http://peachi.labtelenti.org Querying of cellular responses to HIV in vitro (SupT1 cells)
LITCHi http://litchi.labtelenti.org Querying of expression data during HIV latency and upon reactivation in
a primary CD4+ T cell model
G2G http://g2g.labtelenti.org Interactive HIV-host genome-to-genome map of the HLA class I locus
and viral genome variation
External sites
Gene overlapper http://hivsystemsbiology.org/
GeneListOverlapper/
Interactive overlapping of output from genome-wide surveys of host cell
genes linked to HIV infection
NCBI HIV-1 Human protein
interaction database
http://www.ncbi.nlm.nih.gov/projects/
RefSeq/HIVInteractions/
The HIV-1, human protein interaction data are based on literature reports.
Reactome HIV http://reactome.org Visualization, interpretation and analysis of pathway knowledge
VirusMINT – Virus molecular
interaction database
http://mint.bio.uniroma2.it/virusmint/
Welcome.do
Interactions between human and HIV proteins are integrated in the
human protein interaction network
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http://www.retrovirology.com/content/11/1/6from uninfected cells analysed by sequencing [8]. For ex-
ample, Figure 1 illustrates the in vivo and in vitro increase
in TRIM5α expression during active HIV-1 infection. Given
the growing importance of latency research, we also incor-
porated detailed RNA sequencing data on the dynamic
process of entering and maintaining latency in a primary
cell model, and on the expression changes in host and viral
transcripts upon reactivation with various pharmacological
agents and immunological stimuli. GuavaH allows the in-
terrogation of any gene across studies and cellular systems,
and facilitates the validation of expression profiles identified
in other studies.
GuavaH does not report on some additional large-scale
genome-wide data (siRNA, gain-of-function screens) or on
HIV-host protein interactions because these data are con-
veniently available through other open access resources
(see [9] and (Table 1)). GuavaH is also linked to other asso-
ciated resources from our group that allow more detailed
and interactive exploration of the genome-to-genome data,
of the viral replication cycle dynamics, and on the latency
models (Table 1). Expected additions to GuavaH in coming
months are proteome and phosphoproteome data, and
additional transcriptome datasets from primary cell models
of latency.
Promoting easy access to genome-wide association and
functional data fits the goal defined in 2009 by The Global
HIV Vaccine Enterprise of understanding the role of host
genetics in HIV research: “New high-throughput genetic ap-
proaches have the potential to identify major genetic factors
contributing to clinical outcome in HIV-1 infection. Ideally,
every human gene that impacts on each mode of HIV trans-
mission and disease outcome should be identified to improve
our understanding of the mechanisms of protection” [10].
GuavaH is a useful tool for visualizing the host genomic
effects attributable to a given gene of interest and itspotential functional implications in a variety of in vitro
and in vivo settings of HIV infection.
Availability of supporting data
GuavaH provides access to published datasets and to un-
published data upon discussion with the researchers in
charge of the original work. It also allows depositing of
new sets of data for public or private querying. Contact:
contact@guavah.org
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